First Patient Dosed in Newest Stage of Study of Pexa-Vec and Chemo as Sold Tumor Fighter

First Patient Dosed in Newest Stage of Study of Pexa-Vec and Chemo as Sold Tumor Fighter
The first patient has been dosed in the Phase 2 portion of a clinical trial evaluating a combination of the cancer vaccine Pexa-Vec and chemotherapy in solid tumor patients. The dosing at the Institut Bergonié in Bordeaux, France, marks the second stage of the METROmaJX Phase 1/2 trial (NCT02630368). It will evaluate a combination of Pexa-Vec, which

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *